Brodalumab    (DrugBank: Brodalumab)

2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
37膿疱性乾癬(汎発型)3
51全身性強皮症2

37. 膿疱性乾癬(汎発型) [臨床試験数:58,薬物数:50(DrugBank:18),標的遺伝子数:17,標的パスウェイ数:96
Searched query = "Generalised pustular psoriasis", "Pustular psoriasis", "Herpetic impetigo", "Generalization of acrodermatitis continua", "Generalization of dermatitis continua of the extremities"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 58 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04183881
(ClinicalTrials.gov)
July 4, 201629/11/2019A Phase 4 Clinical Study of BrodalumabAn Extension Study of Brodalumab in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic ErythrodermaPsoriasis Vulgaris;Psoriatic Arthritis;Pustular; Psoriasis, Palmaris Et Plantaris;Psoriatic ErythrodermaDrug: Brodalumab 210mg SCKyowa Kirin Co., Ltd.NULLCompleted18 YearsN/AAll138Phase 4Japan
2JPRN-JapicCTI-142430
01/2/2014A Phase 3 Clinical Study of KHK4827An Extension Study of KHK4827 Subjects with Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma PsoriasisIntervention name : KHK4827
INN of the intervention : brodalumab
Dosage And administration of the intervention : Subcutaneous administration
Control intervention name : null
Kyowa Hakko Kirin Co., Ltd.NULL18BOTH165Phase 3NULL
3JPRN-JapicCTI-132057
01/2/2013An open-label, non-controlled study of KHK4827 in subjects with psoriasisA Long-Term Study of KHK4827 in Subjects with Pustular Psoriasis (Generalized) and Psoriatic Erythroderma PsoriasisIntervention name : KHK4827
INN of the intervention : brodalumab
Dosage And administration of the intervention : Subcutaneous administration
Control intervention name : null
Kyowa Hakko Kirin Co., Ltd.NULL18BOTHPhase 3NULL

51. 全身性強皮症 [臨床試験数:466,薬物数:536(DrugBank:142),標的遺伝子数:110,標的パスウェイ数:210
Searched query = "Scleroderma", "Systemic sclerosis", "SSc", "dcSSc", "lcSSc"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 466 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-JapicCTI-194761
23/5/201917/05/2019A Phase 3 study of KHK4827 in patients with systemic sclerosisA Phase 3, placebo-controlled, double-blind comparative study of KHK4827 with an open-label extension period in subjects with systemic sclerosis who have moderate to severe skin thickening Systemic sclerosisIntervention name : KHK4827
INN of the intervention : Brodalumab
Dosage And administration of the intervention : 210 mg Q2W, SC
Control intervention name : Placebo
INN of the control intervention : -
Dosage And administration of the control intervention : 210 mg Q2W, SC
Kyowa Kirin Co., Ltd.NULLcomplete1870BOTH100Phase 3Japan
2JPRN-JapicCTI-173686
06/10/201729/08/2017A Phase 1, open-label, multiple-dose study of KHK4827 in subjects with systemic sclerosisA Phase 1, open-label, multiple-dose study of KHK4827 in subjects with systemic sclerosis systemic sclerosisIntervention name : KHK4827
INN of the intervention : brodalumab
Dosage And administration of the intervention : SC, 210 mg Q2W
Control intervention name : -
INN of the control intervention : -
Dosage And administration of the control intervention : -
Kyowa Kirin Co., Ltd.NULLcomplete1870BOTH6Phase 1Japan